Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 33,504

Document Document Title
WO/2019/009739A1
The invention relates to application of totarol for production of a preparation for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment, and for prophylaxis and preventi...  
WO/2019/007299A1
Disclosed are a salt and a polymorph of a benzopyrimidinone compound and a pharmaceutical composition and the use thereof. In particular, disclosed are a hydrochloride of a benzopyrimidinone compound as shown in the following formula, (I...  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2019/004877A1
The group of inventions relates to medicine and veterinary science, and more particularly to medical and veterinary gynaecology. Proposed is the use of 9-phenyl-sym-octahydroselenoxanthene as an agent for treating female infertility and ...  
WO/2019/003053A1
The present invention relates to an association comprising molecular oxygen and hyaluronic acid for use in the topical treatment of vaginal disorders and, more preferably, for the treatment of vaginal dryness and vulvovaginal atrophy.  
WO/2019/000504A1
Provided are a PDE 5 and a preparation method therefor, and application of the PDE 5 to preparation of drugs used for treating, alleviating or preventing PDE 5-related diseases or disease states of mammals. The structural formula of the ...  
WO/2018/236680A1
Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using isolated populations of mesenchymal stem cells are disclosed.  
WO/2018/233728A1
Provided in the present application are benzo[d]isoxazole compounds, a preparation method therefor and an application thereof. The benzo[d]isoxazole compounds are a group of compounds having novel structures and which act as bromodomain ...  
WO/2018/234342A1
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/233509A1
Disclosed is an abortion drug. The abortion drug comprises a Phaseolus vulgaris phytohemagglutinin, and the concentration of the Phaseolus vulgaris phytohemagglutinin in the abortion drug is 40-60 mg/ml. The abortion drug may comprise a ...  
WO/2018/235926A1
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...  
WO/2018/227829A1
A traditional Chinese medicine, comprising bulk materials of: 12 parts of Root of Ligulilobe Sage, 10 parts of Odoriferous Rosewood, 15 parts of Dodder Seed, 10 parts of Himalayan Teasel Root, 10 parts of Chinese Taxillus Herb, 20 parts ...  
WO/2018/231739A1
The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.  
WO/2018/224063A3
The invention provides novel solid forms of elagolix and its esters of formula (I), optionally with acids or with polymers, methods of preparation and uses thereof. These solid forms are particularly suitable as intermediates of synthesi...  
WO/2018/224498A1
The invention provides methods of treating endometriosis in a patient by administration of a gonadotropin-releasing hormone (GnRH) antagonist, for instance, according to dosing regimens predicated on the patient's level of anti-Mülleria...  
WO/2018/224497A1
The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) ...  
WO/2018/226769A1
Compounds of Formula (I) that antagonize vasopressin receptors, particularly the Via receptor. The compounds are useful for treating e.g. neuropsychological disorders, such as e.g. anxiety, depression and schizophrenia. Preferred compoun...  
WO/2018/221521A1
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...  
WO/2018/219747A1
The present document is directed to a pharmaceutical composition comprising at least one non-ionic cellulose ether, wherein said composition has a viscosity of 35000 cP or more, an osmolality of from about 10 to about 300 mOsmol/kg, and ...  
WO/2018/221966A1
The present invention relates to a pharmaceutical composition for prevention or treatment of bone-related diseases, which promotes the differentiation of preosteoblasts into osteoblasts to induce the formation of calcified nodules and si...  
WO/2018/221679A1
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.  
WO/2018/220126A1
A compound and methods are provided for treating, preventing or ameliorating infertility or reduced fertility in an individual, wherein said compound is capable of regulating the activity of Nuclear Factor, Erythroid 2 Like 2 (NFE2L2).  
WO/2018/216228A1
The purpose of the present invention is to establish, as one of bladder regenerative medical techniques, novel treatment which transplants a bone marrow-derived cell structure into a bladder and attempts to regenerate a functional bladde...  
WO/2018/215433A1
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-...  
WO/2018/214736A1
Provided are a polyhydroxyphthalazinone compound, a preparation method therefor and the use thereof, wherein the general formula of the chemical structure of the polyhydroxyphthalazinone compound is as shown by formula (I). The polyhydro...  
WO/2018/211276A1
The invention relates to a method of reducing sperm motility or of contraception in a subject, said method comprising the step of administering to said subject an effective amount of a compound of formula (I), a stereoisomer, tautomer, p...  
WO/2018/209809A1
The present application relates to a polycrystalline mesylate of a phosphodiesterase type 5 inhibitor. The chemical name of the phosphodiesterase type 5 inhibitor is 5-[2-ethoxy-5-(4-methylpiperazin-1-yl-thiocarbonyl)phenyl]-1 -methyl-3-...  
WO/2018/213125A1
Stromal Derived Factor-1 (SDF-1) is a small, naturally occurring, potent chemokine with inherent angiogenic, neurogenic, anti-apoptotic protein, which is also a potent stem cell chemoattractant, cardiovascular disease, and other metaboli...  
WO/2018/212136A1
The present invention addresses the problem of providing: an antibody having an internalization activity of binding to CDH6; an antibody-drug conjugate consisting of the aforesaid antibody and a drug having an antitumor activity; a medic...  
WO/2018/212256A1
[Problem] To provide a pharmaceutical agent for treatment of pain associated with a gynecological disorder and/or treatment of a structural lesion caused by a gynecological disorder. [Solution] A therapeutic agent for pain associated wit...  
WO/2018/207736A1
The present disclosure relates to a method for introducing a polynucleotide to a male germ cell or Sertoli cell, the method including injection of an adeno-associated virus vector containing the polynucleotide to a testicle of a vertebrate.  
WO/2018/206959A1
The present invention relates to orexin receptor antagonists, pharmaceutical compositi comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists as m...  
WO/2018/206956A1
The present invention relates to orexin receptor antagonists, pharmaceutical compositions comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists a...  
WO/2018/208826A1
A method of enhancing sperm fertility is described herein. The method includes contacting sperm with hydroxyurea. A composition is disclosed that includes sperm, hydroxyurea, and a buffer. Methods, kits, and compositions for enhancing sp...  
WO/2018/205191A1
An industrial preparation method suitable for extracting four types of quassin ingredient from eurycoma longifolia plants, and an application for preparing products. Ultrasonic countercurrent water extraction and silica gel-low boiling p...  
WO/2018/206923A1
The invention relates to multicomponent pharmaceutical compositions which comprise a selective serotonin reuptake inhibitor (SSRI).  
WO/2018/201579A1
Medicated chicken, prepared by employing the following ingredients: 500-1000 g of chicken, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiemalis, 3-9 g of...  
WO/2018/201576A1
A health-promoting fruit wine, prepared by employing the following ingredients: 400-600 g of grape wine, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiem...  
WO/2018/201578A1
Medicated hare or rabbit meat, prepared by employing the following ingredients: 500-1000 g of hare or rabbit meat, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equ...  
WO/2018/201571A1
A traditional Chinese medicine composition for treating dysmenorrhea, prepared by employing the following ingredients: 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba...  
WO/2018/201577A1
A health-promoting fruit wine, prepared by employing the following ingredients: 400-600 g of grape wine, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiem...  
WO/2018/201570A1
A traditional Chinese medicine composition for treating uterine prolapse, prepared by employing the following ingredients: 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of H...  
WO/2018/199748A1
The present invention pertains to a calcium binder for use in improving perinatal survival in the offspring of a sow, and in reducing or preventing stillbirth of piglets. The invention also pertains to compositions comprising a calcium b...  
WO/2018/199749A1
The present invention pertains to a chloride salt for use in improving colostrum intake in offspring of an animal, in improving colostrum production by an animal, and in improving postnatal survival of offspring of an animal. The inventi...  
WO/2018/199166A1
The purpose of the present invention is to provide: compounds having a TrkA inhibiting effect, or pharmacologically acceptable salts thereof, or solvates of these; pharmaceutical compositions characterized by containing these as an activ...  
WO/2018/200977A1
A method for treating a impulse control disorder in a patient comprising administering to the patient an effective amount of pimavanserin or a pharmaceutical acceptable salt thereof.  
WO/2018/199291A1
The purpose of the present invention is to discover a novel compound having an excellent β-lactamase-inhibiting activity, and to provide a useful prophylactic or therapeutic agent for bacterial infectious diseases which comprises a comb...  
WO/2018/192416A1
The invention provides methods of treating male reproductive senescence comprising administering to a male in need thereof a necroptosis inhibitor, including inhibitors of RIP1, RIP3 or MLKL. The invention also provides pharmaceutical co...  
WO/2018/188123A1
Disclosed are a microbial adhesion-rate regulator and application thereof, relating to the field of biotechnology. Said microbial adhesion-rate regulator is suitable for regulating the adhesion rate of micro-organisms to a mucous membran...  
WO/2018/191406A1
This disclosure relates to improved detection of predictors of preeclampsia.  

Matches 1 - 50 out of 33,504